#1 Clinical Trials Search in Europe

Adg126

Clinical trials are investigating Adg126 in people with advanced liver cancers. These studies aim to evaluate how well Adg126 works in immunotherapy-based combinations and how safe the treatment is. The main focus is on treatment response, safety, and lab and heart-related checks in adult patients.

Table of contents

Trial overview

The available study is Morpheus-Liver, a trial called “A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers.”[1]

This is an interventional study, which means researchers assign the treatment plan to the participants instead of only watching what happens naturally.[1]

The trial is in Phase 1, so it is an early study that mainly looks at safety and early signs of benefit.[1]

Who can participate

The study is for patients with advanced liver cancers.[1]

The source data do not list detailed entry rules such as age limits, prior treatments, or lab requirements, so the main known target group is people with this cancer type.[1]

What is being studied

Adg126 is being studied as part of several immunotherapy-based treatment combinations.[1]

The trial title and brief summary show that the study aims to evaluate the efficacy of these combinations, which means how well they work against the cancer, and their safety, which means how well participants tolerate them.[1]

Other study treatments listed in the trial include RO7790118, RO7791094, Tiragolumab, Avastin, RO7247669, Tecentriq, TPST-1120, and RoActemra, showing that the study is testing multiple treatment groups rather than only one plan.[1]

Main outcomes and measurements

The main cancer outcome is objective response rate, or ORR, measured by the investigator using RECIST 1.1.[1]

ORR tells researchers how many patients have a measurable tumor response, such as shrinkage, on imaging scans.[1]

The study also measures the incidence, nature, and severity of adverse events and laboratory abnormalities.[1]

In addition, researchers track changes from baseline in vital signs, ECG parameters, and targeted clinical laboratory test results.[1]

Status and study size

The trial status is Authorised.[1]

The planned enrollment is 309 participants, which means the study is designed to include 309 people in total.[1]

Trial ID Phase Condition studied Status Enrollment
2023-506611-17-00 Phase 1 Advanced liver cancers Authorised 309

FAQ

  • What is being studied in Adg126 clinical trials? The trials are testing Adg126 as part of immunotherapy-based treatment combinations. Researchers want to see whether these combinations can help people with advanced liver cancers and whether they are safe.
  • Who may take part in these studies? The study is for patients with advanced liver cancers. It is an interventional trial, which means participants receive a study treatment rather than only being observed.
  • What phase is the Adg126 trial? The available trial is a Phase 1 study. Phase 1 studies mainly look at safety and early signs of how well a treatment works.
  • What results are the researchers measuring? The main result is objective response rate, or ORR, which means how many patients have a measurable tumor response. The study also checks side effects, lab tests, vital signs, and ECG results.
  • How many people are planned for the Adg126 study? The trial plans to enroll 309 people. This gives researchers enough patients to study several treatment combinations in advanced liver cancer.

Ongoing Clinical Trials on Adg126

  • Study on the Effectiveness and Safety of TPST-1120 and Drug Combination for Patients with Advanced Liver Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Advanced liver cancers: Cancers of the liver that have spread or are at a later stage, making treatment more complex.
  • Immunotherapy: A type of treatment that helps the immune system fight cancer.
  • Treatment combination: Two or more treatments used together in one study plan.
  • Phase 1: An early clinical trial phase that mainly checks safety and looks for early signs that a treatment may work.
  • Interventional study: A study where participants receive a treatment or treatment plan chosen by the researchers.
  • Objective response rate (ORR): The percentage of patients whose tumors shrink or disappear in a way that can be measured.
  • RECIST 1.1: A standard way doctors use scans to measure whether a cancer treatment is working.
  • Adverse events: Medical problems or side effects that happen during a study, whether or not they are caused by the treatment.
  • Laboratory abnormalities: Unusual blood or urine test results that may show a problem in the body.
  • ECG: A heart test that records the electrical activity of the heart.
  • Vital signs: Basic body checks such as blood pressure, pulse, temperature, and breathing rate.

References